Immunovant, Inc. (IMVT)
Automate Your Wheel Strategy on IMVT
With Tiblio's Option Bot, you can configure your own wheel strategy including IMVT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMVT
- Rev/Share 0.0102
- Book/Share 2.4
- PB 6.2041
- Debt/Equity 0.0001
- CurrentRatio 6.0388
- ROIC -1.1507
- MktCap 2529230290.0
- FreeCF/Share -2.2164
- PFCF -7.7669
- PE -5.7163
- Debt/Assets 0.0001
- DivYield 0
- ROE -0.7794
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IMVT | Jefferies | -- | Hold | -- | $20 | March 3, 2025 |
| Downgrade | IMVT | Wolfe Research | Outperform | Peer Perform | -- | -- | Jan. 3, 2025 |
| Resumed | IMVT | Raymond James | -- | Outperform | -- | $36 | Oct. 10, 2024 |
| Reiterated | IMVT | Oppenheimer | -- | Outperform | $47 | $53 | Oct. 9, 2024 |
News
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Read More
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Published: March 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant's directors breached their fiduciary duties in connection with recent corporate actions.
Read More
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Published: March 19, 2025 by: Investors Business Daily
Sentiment: Positive
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Read More
About Immunovant, Inc. (IMVT)
- IPO Date 2019-06-21
- Website https://immunovant.com
- Industry Biotechnology
- CEO Dr. Eric Venker M.D., Pharm.D.
- Employees 207